RRAD: A Potential Drug Target and Biomarker for Various Diseases

Target Name: RRAD

NCBI ID: G6236

RRAD

RRAD: A Potential Drug Target and Biomarker for Various Diseases

RRAD (Resorcin A) is a peptide that is derived from the venom of the cobra worm, and it has been shown to have a variety of potential drug-like properties. In this article, we will discuss the potential of RRAD as a drug target and its potential as a biomarker for various diseases.

The cobra worm, also known as the Indian cobra, is a venomous snake that is found in India and other parts of the world. The venom of this worm contains a variety of bioactive molecules that have been shown to have a variety of potential medical applications . One of these molecules is resorcin A (RRAD), which is a peptide that is derived from the venom of the cobra worm.

RRAD has been shown to have a variety of potential drug-like properties, including its ability to interact with various cell types and its ability to modulate cellular signaling pathways. In addition, RRAD has been shown to have a variety of potential applications in treating a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key potential applications of RRAD is its ability to act as a drug target. RRAD has been shown to interact with a variety of different proteins, including G protein-coupled receptors (GPCRs) and tyrosine kinase receptors (TKRs). These proteins are involved in a variety of cellular signaling pathways, and modulating them can be a potential way to treat a variety of diseases.

In addition to its potential as a drug target, RRAD has also been shown to be a potential biomarker for a variety of diseases.RRAD has been shown to be expressed in a variety of different tissues and cells, including cancer cells, neurodegenerative cells, and immune cells. This makes it a potential biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

RRAD has also been shown to have a variety of potential applications in treating a variety of diseases. RRAD has been shown to be effective in treating a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that RRAD can be used to treat various forms of cancer, including breast, ovarian, and prostate cancer. In addition, RRAD has also been shown to be effective in treating neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In conclusion, RRAD is a peptide that is derived from the venom of the cobra worm and has a variety of potential drug-like properties. In this article, we have discussed the potential of RRAD as a drug target and its potential as a biomarker for various diseases. Further research is needed to fully understand the potential of RRAD and its potential as a treatment for a variety of diseases.

Protein Name: RRAD, Ras Related Glycolysis Inhibitor And Calcium Channel Regulator

Functions: May regulate basal voltage-dependent L-type Ca(2+) currents and be required for beta-adrenergic augmentation of Ca(2+) influx in cardiomyocytes, thereby regulating increases in heart rate and contractile force (By similarity). May play an important role in cardiac antiarrhythmia via the strong suppression of voltage-gated L-type Ca(2+) currents (By similarity). Regulates voltage-dependent L-type calcium channel subunit alpha-1C trafficking to the cell membrane (By similarity). Inhibits cardiac hypertrophy through the calmodulin-dependent kinase II (CaMKII) pathway (PubMed:18056528). Inhibits phosphorylation and activation of CAMK2D (PubMed:18056528)

The "RRAD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RRAD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets